Covid-19 therapy developer on the Main Line has another strong day on Wall Street

NRx Pharmaceuticals' stock continued to soar Friday, a day after the Radnor company announced it had validated the first commercial formulation of its experimental Covid-19 treatment. In mid-afternoon trading, NRx (NASDAQ: NRXP) shares were trading up more than 31% at $21.61 per share. When the bell rang, the stock was up 50% at $24.77. On Thursday, the stock closed up 62.7% at $16.45 per share. NRx is developing Zyesami as an intravenous treatment for respiratory failure in critically-ill patients…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news